Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to "Hold" at Wall Street Zen

Wall Street Zen downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) from a buy rating to a hold rating in a research note published on Saturday morning.

Several other equities analysts have also issued reports on the company. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Chardan Capital boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. HC Wainwright restated a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Morgan Stanley decreased their price objective on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Finally, Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price target for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $319.58.

Alnylam Pharmaceuticals Trading Down 0.0%

Shares of NASDAQ:ALNY traded down $0.07 during trading on Friday, hitting $308.71. 570,555 shares of the company's stock were exchanged, compared to its average volume of 931,065. Alnylam Pharmaceuticals has a 1-year low of $152.30 and a 1-year high of $322.97. The firm has a 50-day moving average price of $273.09 and a two-hundred day moving average price of $259.83. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The firm has a market cap of $40.25 billion, a P/E ratio of -147.71 and a beta of 0.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same period in the prior year, the firm posted ($0.16) EPS. Alnylam Pharmaceuticals's revenue was up 20.2% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer now directly owns 48,948 shares in the company, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.20% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Truist Financial Corp grew its position in Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after purchasing an additional 2,539 shares during the period. Ieq Capital LLC grew its holdings in shares of Alnylam Pharmaceuticals by 825.5% during the fourth quarter. Ieq Capital LLC now owns 38,806 shares of the biopharmaceutical company's stock valued at $9,131,000 after buying an additional 34,613 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares during the last quarter. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. Finally, Silvercrest Asset Management Group LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $1,151,000. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.